COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
Want to see CH:COPN full AI Analyst Report?
COPN Stock Chart & Stats
CHF97.80
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF97.80
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF49.35 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.23B
Enterprise ValueCHF1.24B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF143.33Price Target Upside46.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.78
Revenue Forecast (FY)CHF121.86M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet With Minimal LeverageA very low debt load and sizable equity (~€482M in 2025) give Cosmo durable financial flexibility. This balance-sheet strength supports R&D funding, absorption of revenue volatility, selective partnerships or bolt-on deals, and reduces refinancing risk during downturns.
Diversified Revenue Model: Sales Plus LicensingThe mix of direct commercialization and licensing (upfronts, milestones, royalties) provides multiple cash-flow channels. Over time this reduces dependence on single-product launches, smooths receipts, and aligns incentives with partners, improving revenue resilience.
Niche Focus In Gastroenterology And EndoscopyA concentrated product and technology focus in gastroenterology/endoscopy creates specialized expertise and clinician relationships. This niche positioning can lead to higher barriers to entry, targeted R&D efficiency, and more defensible commercial routes versus broad-based peers.
Bears Say
Sharp Revenue And Profit VolatilityAfter an exceptional 2024, the abrupt 2025 revenue decline and margin erosion highlight unstable demand or one-off drivers. Persistent volatility undermines forecasting, complicates multi-quarter planning, and reduces confidence in the sustainability of operating results.
Deteriorating Cash Generation In 2025The swing from large positive cash flow in 2024 to negative operating and free cash flow in 2025 weakens self-funding capacity. Continued cash burn would force external financing or program cuts, reducing strategic optionality and pressuring investments or payouts.
Inconsistent Historical ProfitabilityA record of intermittent losses and severe EPS contraction indicates earnings depend on episodic factors. This inconsistent profitability raises execution and partner risk, increases the cost of capital, and complicates long-term investment decisions for the business.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF49.35 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.23B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 29, 2026 which is in 80 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.092 earnings per share for the quarter, missing the consensus estimate of CHF0.183 by -CHF0.275.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.918 which represents an annual dividend yield of 1.82%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.092 in its last earnings report, missing expectations of CHF0.183. Following the earnings report the stock price went down -10.522%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF143.33
▲(46.56% Upside)
Technical Analysis
Options Prices
Currently, No data available
---